Atrion (ATRI) Upgraded to “Strong-Buy” at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Atrion (NASDAQ:ATRI) from a buy rating to a strong-buy rating in a research note published on Friday morning.

Shares of NASDAQ ATRI opened at $722.11 on Friday. Atrion has a 12 month low of $516.85 and a 12 month high of $734.90. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of 38.40 and a beta of 0.56.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 17th. Shareholders of record on Monday, December 3rd will be issued a $1.35 dividend. The ex-dividend date of this dividend is Friday, November 30th. This represents a $5.40 annualized dividend and a yield of 0.75%.

Hedge funds and other institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. bought a new position in Atrion in the 1st quarter worth $249,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new position in shares of Atrion in the 2nd quarter worth about $240,000. Chevy Chase Trust Holdings Inc. bought a new position in shares of Atrion in the 2nd quarter worth about $300,000. Bank of Montreal Can bought a new position in shares of Atrion in the 2nd quarter worth about $362,000. Finally, WINTON GROUP Ltd bought a new position in shares of Atrion in the 2nd quarter worth about $396,000. Institutional investors and hedge funds own 63.74% of the company’s stock.

About Atrion

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Further Reading: What is insider trading?

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.